Cullinan Therapeutics (NASDAQ: CGEM) said it will hold a virtual event Monday at 8:00 a.m. ET for analysts and institutional investors to discuss results from the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy as a first-line treatment for patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive non-small cell lung cancer.
Chief Executive Officer Nadim Ahmed and Chief Medical Officer Jeffrey Jones are scheduled to lead the session. A live webcast will be available on the company’s investor relations website, with an archived replay to follow.
The company previously disclosed that REZILIENT3 met its primary endpoint — progression-free survival — at a planned interim analysis. Data from that interim read will be presented Sunday at Presidential Symposium 2 during the International Association for the Study of Lung Cancer’s 2026 World Conference on Lung Cancer, taking place September 12–15 in Seoul, South Korea.
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing T cell engagers for autoimmune diseases and cancer.
